Avails Medical has developed digital technology to provide accurate, rapid detection of infections.
Rapid digital detection of infections and treatment optimization. Accurate, rapid, digital detection of infections in any bodily fluid to indicate in real-time which drugs will be most effective at the point-of-prescription.
Today the US spends $20B+ on infection detection. The market for efficient bacteria resistance detection has enormous potential. Avails Medical is pioneering the current diagnostics market with a groundbreaking technology that targets this global health threat.
Avails Medicals' cost-effective platform will transform the diagnostics market by enabling for the first time diagnostic-guided therapy at the point-of-care, reducing time-to-treatment from days to minutes.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 1, 2021 | Grant | $2.50M | 1 | CARB-X | — | Detail |
Mar 24, 2020 | Series Unknown | — | 3 | Omron Ventures | — | Detail |
Feb 9, 2017 | Series B | $6.36M | — | — | — | Detail |
Jul 28, 2016 | Seed | $500K | — | — | — | Detail |
Mar 24, 2016 | Debt Financing | $550K | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
CARB-X | Yes | Grant |
Omron Ventures | Yes | Series Unknown |
Newton Fund | — | Series Unknown |
Propel(X) | — | Series Unknown |
The Explorer Group | — | Debt Financing |